日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors

PTPRR下调诱导的组成型EGFR激活赋予KRAS抑制剂耐药性

Kanemura, Hiroaki; Takehara, Toshiyuki; Maenishi, Osamu; Tomida, Shuta; Iwawaki, Natsumi; Kunimasa, Kei; Nakayama, Tomohiro; Watanabe, Satomi; Suzuki, Shinichiro; Sakai, Kazuko; Azuma, Koichi; Kudo, Keita; Nishio, Kazuto; Nakagawa, Kazuhiko; Hayashi, Hidetoshi; Teramura, Takeshi; Yonesaka, Kimio

Development of Second Primary Malignancies in Long-term Survivors of Unresectable Esophageal Cancer

不可切除食管癌长期生存者发生第二原发性恶性肿瘤的情况

Watanabe, Ryotaro; Mitani, Seiichiro; Okura, Masaki; Inagaki, Chiaki; Tanizaki, Junko; Tanaka, Kaoru; Iwasa, Tsutomu; Yonesaka, Kimio; Hayashi, Hidetoshi

Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer.

染色体不稳定性与 EGFR-TKI 耐药性非小细胞肺癌中的 cGAS-STING 激活相关

Yonesaka Kimio, Kurosaki Takashi, Tanizaki Junko, Kawakami Hisato, Tanaka Kaoru, Maenishi Osamu, Takamura Shiki, Sakai Kazuko, Chiba Yasutaka, Teramura Takeshi, Goto Hiroki, Otsuka Eri, Okida Hiroaki, Funabashi Masanori, Hashimoto Yuuri, Hirotani Kenji, Kamai Yasuki, Kagari Takashi, Nishio Kazuto, Kakimi Kazuhiro, Hayashi Hidetoshi

Zongertinib, a Novel HER2 Tyrosine Kinase Inhibitor, Maintains an Anticancer Activity for Trastuzumab Deruxtecan-Resistant Cancers Harboring HER2-Overexpression

新型HER2酪氨酸激酶抑制剂Zongertinib对HER2过表达且对曲妥珠单抗Deruxtecan耐药的癌症仍保持抗癌活性。

Kurosaki, Takashi; Suzuki, Shinichiro; Yonesaka, Kimio; Kawanaka, Yusuke; Takehara, Toshiyuki; Teramura, Takeshi; Sakai, Kazuko; Nishio, Kazuto; Hayashi, Hidetoshi

Case Report: A small cell lung cancer transformed from an EGFR-mutated Adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody

病例报告:一例由EGFR突变腺癌转化而来的小细胞肺癌患者,在接受抗PD-1抗体治疗后,获得了长期缓解。

Kawanaka, Yusuke; Yonesaka, Kimio; Tanizaki, Junko; Maenishi, Osamu; Sakai, Kazuko; Kakimi, Kazuhiro; Nishio, Kazuto; Hayashi, Hidetoshi

Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinoma

同源重组介导的基因改变对胰腺导管腺癌预后的影响:DNA修复基因改变状态

Kawanaka, Yusuke; Inagaki, Chiaki; Okura, Masaki; Mitani, Seiichiro; Takahama, Takayuki; Yonesaka, Kimio; Chiba, Yasutaka; Nakagawa, Kazuhiko; Kawakami, Hisato; Hayashi, Hidetoshi

Detection of Overlooked Rare EGFR Mutations in Non-small Cell Lung Cancer Using Multigene Testing

利用多基因检测发现非小细胞肺癌中被忽略的罕见EGFR突变

Shiraishi, Naoki; Takahama, Takayuki; Sakai, Kazuko; Tanaka, Kaoru; Nakagawa, Yuzuki; Kanemura, Hiroaki; Nakayama, Tomohiro; Kawanaka, Yusuke; Kurosaki, Takashi; Suzuki, Shinichiro; Iwasa, Tsutomu; Tanizaki, Junko; Inagaki, Chiaki; Yonesaka, Kimio; Fukuoka, Kazuya; Mitsudomi, Tetsuya; Nishio, Kazuto; Hayashi, Hidetoshi; Nakagawa, Kazuhiko

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer?

PHAROS 2 期研究的最新结果:恩科拉非尼联合比美替尼治疗 BRAF V600E 突变转移性非小细胞肺癌患者的疗效和耐受性是否得到证实?

Yonesaka, Kimio

Malignant transformation of an ovarian mature teratoma diagnosed 17 years ago: a case report and literature review of treatment with immune checkpoint inhibitors

17年前诊断的卵巢成熟畸胎瘤发生恶性转化:病例报告及免疫检查点抑制剂治疗的文献综述

Nagayama, Akiho; Miyagawa, Chiho; Kashima, Yoko; Ohta, Mamiko; Otani, Tomoyuki; Kurosaki, Takashi; Isomoto, Kohsuke; Inagaki, Chiaki; Takahama, Takayuki; Yonesaka, Kimio; Hayashi, Hidetoshi; Sakai, Kazuko; Nishio, Kazuto; Nakagawa, Kazuhiko; Matsumura, Noriomi

Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database

通过全面的基因组分析,评估免疫检查点抑制剂对CD274(PD-L1基因)扩增的实体瘤的疗效:一项基于全国数据库的回顾性研究

Nakayama, Tomohiro; Takahama, Takayuki; Chiba, Yasutaka; Shiraishi, Naoki; Kawakami, Hisato; Yonesaka, Kimio; Nakagawa, Kazuhiko; Hayashi, Hidetoshi